IDH2 and neoplasm: In the whole cohort (n = 60), the univariate survival analysis revealed that glioma patients with IDH-mutant tumours had significantly longer PFS (33 vs. 9 months) and OS (54 vs. 13 months) than patients with IDH-wildtype gliomas (both P < 0.001).